These presentations are intended for investors and analysts for financial purposes and are not intended for health care practitioners. Health care practitioners with questions regarding these presentations are referred to InterMune Medical Information at 1(888) 486-6411.
BRISBANE, Calif., Feb. 2, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full year 2011 financial results at the close of the U.S. markets on Thursday, February 9, 2012. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.
Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1-212-271-4651 (international), conference ID# 2157...
- Company to host conference call and webcast today at 8:30 a.m. EST -
BRISBANE, Calif., Jan. 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited net sales of Esbriet® (pirfenidone) for the fourth quarter ended December 31, 2011, as well as information on the number of patients that initiated Esbriet therapy in Germany during 2011. InterMune also highlighted its recent business and clinical development activities, including new efficacy da...
BRISBANE, Calif., Jan. 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2012, at 12:30 p.m. EST / 9:30 a.m. PST.
To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.c...
- Conference call and webcast will be hosted on January 5 at 8:30 a.m. EST -
BRISBANE, Calif., Jan. 4, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will report unaudited fourth quarter 2011 revenue related to sales of Esbriet® (pirfenidone) in Germany, as well as other metrics related to the Esbriet launch, prior to the open of the U.S. markets on Thursday, January 5, 2012. A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time...
Transfer Agent
Mellon Investor Services LLC 525 Market Street, Suite 3500 San Francisco, CA 94105 Phone: 877-854-4572 (Dedicated number for InterMune) Fax: 415-951-4181 www.bnymellon.com/shareowner/isd
Independent Accountants
Ernst & Young LLP
Nothing on this website constitutes or is intended to constitute an invitation or offer to invest or deal in the securities of Intermune.
Except for the historical information contained herein, this website contains certain forward-looking statements that involve risks and uncertainties. You can identify those statements by the fact that they contain words such as "anticipate," "believe," "estimate," "expect," "potential," "intend," "project," or other terms of similar meaning. InterMune’s actual results may differ materially from those described in the forward-looking statements. All forward-looking statements and other information included in this website are based on information available to InterMune as of August 1, 2010, and InterMune assumes no obligation to update any such forward-looking statements or information. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" and the other risks and factors discussed in InterMune’s most recent Form 10-K and other periodic filings (i.e., 8-K and 10-Q) filed with the Securities and Exchange Commission. The SEC’s website is http://www/sec/gov, and our filings are contained in the SEC’s Edgar archives. Please see the Terms and Conditions of Access and Use section of this website for a listing of InterMune’s "Risk Factors," which are discussed in the periodic filings filed with the SEC.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Summary of Product Characteristics (SmPC) for Esbriet® (pirfenidone)
